|
An open label, multicenter, phase 1b/2 study of rebastinib (DCC-2036) in combination with carboplatin to assess safety, tolerability, and pharmacokinetics in patients with advanced or metastatic solid tumors. |
|
|
Employment - Next Oncology; START |
|
Consulting or Advisory Role - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aro BioTX (Inst); Ascentage Pharma (Inst); Aximmune (Inst); Bayer (Inst); BioInvent (Inst); BioInvent (Inst); Birdie Bio (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Forbius (Inst); HBM Partners (Inst); Ignyta (Inst); Immunome (Inst); Immunome (Inst); Jazz Pharmaceuticals (Inst); Mekanistic Therapeutics (Inst); Nanobiotix (Inst); NBE Therapeutics (Inst); Nuvalent, Inc. (Inst); Pelican Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Ridgeway (Inst); Scientex (Inst); Seagen (Inst); Sesen Bio (Inst); Symphogen (Inst); Syneos Health (Inst) |
Research Funding - AbbVie (Inst); Adagene (Inst); ADC Therapeutics (Inst); Aminex (Inst); Arrys Therapeutics (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie Biomedical (Inst); CStone Pharmaceuticals (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Innate Pharma (Inst); Kiromic (Inst); Mersana (Inst); Naturewise (Inst); NextCure (Inst); Nitto BioPharma (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Symphogen (Inst); Syndax (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst) |
|
|
Stock and Other Ownership Interests - OncoSec (I) |
Honoraria - Amgen (I); Prometheus (I); Threshold Pharmaceuticals |
Consulting or Advisory Role - HUYA Bioscience International |
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst) |
|
|
Research Funding - Bayer (Inst); Lilly (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Regeneron (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Deciphera; Evelo Therapeutics (I); Karyopharm Therapeutics; Momenta Pharmaceuticals (I) |
Stock and Other Ownership Interests - Karyopharm Therapeutics; Momenta Pharmaceuticals (I) |
|
|
|
Stock and Other Ownership Interests - Deciphera; Vertex |
|
|
|
Stock and Other Ownership Interests - Deciphera; Immunogen |
Patents, Royalties, Other Intellectual Property - I am an inventor in 3 patents with Immunogen, I transferred the rights to Immunogen. I have not received (and I will not receive) any royalties |
|
|
Stock and Other Ownership Interests - Trovagene |
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IFM Therapeutics; Immunome; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon |
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Roche (Inst); Symphogen (Inst) |
Other Relationship - Bio-Rad |